Aniling chosen for an intensive preparation program for Boston
The IGTP-PMPPC applied health technology spin-off is one of five selected by ACCIÓ in the first edition of 'Road to Boston'
Aniling is one of five applied health technology Catalan start-ups that has started an intensive six-month tailored program to prepare for entry to Boston, one of the principal hubs in this field, to establish first contacts with key players in the sector. ACCIÓ (Agency for Business Competitiveness, of the Department of Business and Knowledge) is organizing this first edition of the programme through the Catalonia Trade & Investment Office in Boston; a pilot was run in 2017.
The objective of the programme is to provide tailored support to start-ups in the scaling up phase so they can validate their business models and enter the North American market; accessing possible clients in large pharmaceutical companies, hospitals and universities in the capital of Massachusetts. Along with Aniling Medtep, PlayBenefit, 8wires and Ascil Biopharm have also been selected.
During the six months the start-ups will receive an integrated tailored consulting service from Barcelona and from a team of experts and mentors from organisations such as the Massachusetts Institute of Technology (MIT) and the Massachusetts Technology Transfer Center, amongst others in areas such as product strategy, communications and legal aspects. Managers from the companies will also travel to the United States twice, firstly to meet their mentors in person to prepare a communications strategy and a pitch to present to possible clients, share-holders or local investors. They will also attend trade fairs and international meetings, networking events and first meetings with local players during these trips.
The Catalan start-ups selected for this programme are part of the more than 1,250 start-ups identified by the Barcelona & Catalonia Startup Hub directory compiled by ACCIÓ.
Founded in 2014 Aniling works with a unique technology to carry out high quality analysis of the genome and epigenome simultaneously. It has recently been selected as one of the 10 Catalan start-ups with most growth potential by the newspaper L’Econòmic. Its objective is to accelerate scientific advances in genomics and epigenomics through the development of applied technologies and it centres on the improvement of two Next Generation Sequencing methods to integrate molecular data with biologically significant information to the high standards required for clinical use.